^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ATG-018

    i
    Company:
    Antengene
    Drug class:
    ATR inhibitor
    Related drugs:
    Apply
    A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies (ATRIUM) (NCT05338346)
    Phase 1
    Antengene Discovery Limited
    Recruiting
    Last update posted :
    04/22/2024
    Initiation :
    07/08/2022
    Primary completion :
    06/30/2024
    Completion :
    06/30/2024
    BRCA1 • BRCA2 • ATM • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC
    |
    TP53 mutation • FANCF mutation
    |
    ATG-018